Research Oncology, 3rd Floor Bermondsey Wing, Guy's Hospital, London SE1 9RT, UK.
Breast. 2018 Apr;38:132-135. doi: 10.1016/j.breast.2018.01.001. Epub 2018 Jan 6.
Important differences have begun to emerge concerning the molecular profile of female and male breast cancer which may prove to be of therapeutic value. This review examined all the available data on the genomics of MBC. Most male cancers are ER+ve but without a corresponding increase in PR positivity and only a weaker association with estrogen-controlled markers such as PS2, HSP27 and Cathepsin-D. HER2 +ve cancers are rare in males and the role of androgen receptor is controversial. Although the Luminal A phenotype was the most frequent in both MBC and FBC, no Luminal B or HER2 phenotypes were found in males and the basal phenotype was very rare. Using hierarchical clustering in FBC, ERα clustered with PR, whereas in MBC, ERα associated with ERβ and AR. Based on limited data it appears that Oncotype DX is effective in determining recurrence risk in selected MBC. In future, tailored therapies based on genomics will probably yield the most promising approach for both MBC and FBC.
在女性和男性乳腺癌的分子特征方面已经开始出现重要差异，这些差异可能具有治疗价值。本综述检查了关于男性乳腺癌基因组学的所有现有数据。大多数男性癌症为 ER+，但 PR 阳性率没有相应增加，与雌激素控制标志物如 PS2、HSP27 和组织蛋白酶-D 的相关性也较弱。HER2+癌症在男性中罕见，雄激素受体的作用存在争议。虽然在男性乳腺癌和女性乳腺癌中最常见的是 Luminal A 表型，但未发现 Luminal B 或 HER2 表型，基底表型非常罕见。在女性乳腺癌中，使用分层聚类，ERα与 PR 聚类，而在男性乳腺癌中，ERα与 ERβ和 AR 相关。根据有限的数据，Oncotype DX 似乎在确定选定的男性乳腺癌的复发风险方面有效。未来，基于基因组学的定制疗法可能会为男性乳腺癌和女性乳腺癌带来最有希望的治疗方法。
